To identify these cancer stem cells, several new cell-surface markers of breast cancer associated with the CSC lineage have been discovered, such as the presence of CD44 (CD44high) combined with the (near-)absence of CD24 (CD24low), so CD44 was deemed an important biomarker and therapeutic target of this cancer [8]. This evidence concerns the gene CD44 and breast carcinoma.